Clinical Report: Study Finds Radiation Therapy Administered Before Surgery Rarely Shrinks Retroperitoneal Sarcoma Tumors

Overview

A recent study from Fox Chase Cancer Center reveals that pre-surgical radiation therapy rarely leads to significant tumor shrinkage in retroperitoneal sarcoma patients, with only 4.5% showing a partial response. The findings align with the STRASS trial, suggesting that preoperative radiation does not improve surgical outcomes.

Background

Retroperitoneal sarcoma (RPS) is a rare and aggressive cancer that often presents at an advanced stage, making surgical intervention the primary treatment option. The complexity of RPS surgeries is heightened due to tumor invasion into vital organs. Understanding the efficacy of pre-surgical treatments like radiation is crucial for optimizing patient outcomes.

Data Highlights

Key Findings

• Only 1 out of 22 patients (4.5%) experienced meaningful tumor shrinkage with pre-surgical radiation.
• Over 75% of patients showed no significant change in tumor size.
• 18% of patients experienced tumor growth during radiation therapy.
• No differences in surgical complexity were observed between patients who responded to radiation and those who did not.
• None of the patients with tumors encasing adjacent organs showed changes in organ involvement after radiation.

Clinical Implications

The study suggests that preoperative radiation therapy should be avoided in most RPS patients, as it does not lead to significant tumor shrinkage or reduced surgical complexity. Clinicians may consider moving directly to surgery to optimize patient outcomes.

Conclusion

The findings reinforce the notion that pre-surgical radiation is ineffective for RPS and support a shift towards immediate surgical intervention for affected patients.

References

1. Fox Chase Cancer Center, EurekAlert!, 2023 -- Study finds radiation therapy administered before surgery rarely shrinks retroperitoneal sarcoma tumors
2. Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial - ScienceDirect
3. UK guidelines for the management of soft tissue sarcomas
4. fox chase cancer center — Adaptive Radiation Therapy Increases Safety and Preserves Quality of Life, Says Study
5. the asco post — CT-Adapative SBRT for Recurrent Retroperitoneal Sarcomas
6. The ASCO Post — Expert Point of View: Rebecca A. Snyder, MD, MPH
7. The ASCO Post — Preoperative Radiotherapy Dose Reduction in Patients With Myxoid Liposarcoma
8. Adaptive Radiation Therapy Increases Safety and Preserves Quality of Life, Says Study
9. CT-Adapative SBRT for Recurrent Retroperitoneal Sarcomas
10. Expert Point of View: Rebecca A. Snyder, MD, MPH
11. UK guidelines for the management of soft tissue sarcomas
12. Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial - ScienceDirect
13. Study finds radiation therapy administered before surgery rarely shrinks retroperitoneal sarcoma tumors | EurekAlert!